Nanotechnology for Medical Diagnostics and Treatment
Sunday May 7, 2006, 8:00 am - 6:00 pm, Boston, MA
Nanotechnology has the potential to have a revolutionary impact on medical
diagnosis and therapy. It is universally accepted that early detection of cancer
is essential even before anatomic anomalies are visible. A major challenge in
cancer diagnosis in the 21st century is to be able to determine the exact
relationship between cancer biomarkers and the clinical pathology, as well as,
to be able to non-invasively detect tumors at an early stage for maximum
therapeutic benefit. For breast cancer, for instance, the goal of molecular
imaging is to be able to accurately diagnose when the tumor mass has
approximately 100-1000 cells, as opposed to the current techniques like
mammography, which require more than a million cells for accurate clinical
In cancer therapy, targeting and localized delivery are the key challenges. To
wage an effective war against cancer, we have to have the ability to selectively
attack the cancer cells, while saving the normal tissue from excessive burdens
of drug toxicity. However, because many anticancer drugs are designed to simply
kill cancer cells, often in a semi-specific fashion, the distribution of
anticancer drugs in healthy organs or tissues is especially undesirable due to
the potential for severe side effects. Consequently, systemic application of
these drugs often causes severe side effects in other tissues (e.g. bone marrow
suppression, cardiomyopathy, neurotoxicity), which greatly limits the maximal
allowable dose of the drug. In addition, rapid elimination and widespread
distribution into non-targeted organs and tissues requires the administration of
a drug in large quantities, which is often not economical and sometimes
complicated due to non-specific toxicity. This vicious cycle of large doses and
the concurrent toxicity is a major limitation of current cancer therapy. In many
instances, it has been observed that the patient succumbs to the ill effects of
the drug toxicity far earlier than the tumor burden.
This course will address the state of the art in nanotechnologies and
nano-medicine, and their ongoing applications focused on addressing the
challenges posed by cancer prevention, diagnosis and treatment. Distinguished
instructors will summarize the basics of nanotechnology and cancer biology,
along with the current technologies, trials and future barriers. This program is
designed to inform cancer researchers, clinicians, bio-nano technologists,
technology managers, and business developers of the state of the art in bio nano
technologies, focusing on applications of these technologies for cancer
prevention, diagnosis and treatment.
Nanotechnology for Cancer – Overview
- Cancer biology fundamentals
- Physiology of tumorigenesis, vasculature, etc.
- Clinical aspects and current approaches
- Unmet needs in clinical setting
Nanotechnology for Imaging - detection and therapy
- Fluorophores and Quantum dots
- Labeling and functionalization
- Image analysis
- Imaging facilitating surgical approaches
Nanotechnology for Cancer Therapy
- Challenges in cancer therapy
- Role of nanotechnology in cancer therapy
- Nanotechnology platforms
- Properties of nanoplatforms
Nanotechnology for Cancer Therapy
- Passive versus active targeting
- Tumor-targeted drug delivery systems (DNA, siRNA, etc)
- Nanoparticles: silica, vesicles, dendrimers, etc.
- Drug encapsulation strategies
- Multifunctional nanotherapeutics
- Radio-sensitization and tumor ablation with nanoparticles
Nanotechnology in Cancer Research 1
- Genome and proteome perturbations: overview
- Protein and nucleic acid markers: handle for early detection
- Current methodology and instrumentation
Nanotechnology in Cancer Research 2
- Why miniaturize?
- Advanced separations: fluidics
- Interfaces to measurement techniques
Nanotechnology for Cancer Diagnosis and Treatment
Mansoor Amiji, Ph.D., Associate Professor of Pharmaceutical Sciences in the School of
Pharmacy, Bouve College of Health Sciences and Associate Director of the
Nanomedicine Consortium, Northeastern University in Boston, MA.
Dr. Amiji received his undergraduate degree in pharmacy from
Northeastern University in 1988 and his Ph.D. in
pharmaceutics/biomaterial science from Purdue University in 1992. His
areas of specialization include polymeric biomaterials, drug delivery
systems, and nanomedical technologies.
Dr. Amiji’s research interests include synthesis of novel polymeric
materials for medical and pharmaceutical applications; surface
modification of cationic polymers by the complexation-interpenetration
method to develop biocompatible materials; preparation and
characterization of polymeric membranes and microcapsules with
controlled permeability properties for medical and pharmaceutical
applications; target-specific drug and vaccine delivery systems for
gastrointestinal tract infections; localized delivery of cytotoxic and
antiangiogenic drugs for solid tumors in novel biodegradable polymeric
nanoparticles intracellular delivery systems for drugs and genes using
target-specific, long-circulating, biodegradable polymeric
nanoparticles; gold and iron-gold core-shell nanoparticles for
biosensing, imaging and delivery applications. His research has received
funding from the National Institutes of Health, local biotechnology and
medical device industries, and private foundations.
Dr. Amiji has extensively published research articles, book chapters,
and conference proceedings. He has also published two books - Applied
Physical Pharmacy (McGraw-Hill, 2003) and Polymeric Gene Delivery
Systems: Principles and Applications (CRC Press, 2004). Dr. Amiji has
received a number of awards and accolades including the third prize of
Eurand Award for Outstanding Research in Oral Drug Delivery in 2003.
Srinivas Iyer, Ph.D., Technical Staff Member, Bioscience Division, Los Alamos National
Laboratory, New Mexico, USA. Dr. Iyer has a Ph.D. from the University of
Houston in biochemistry, with extensive experience in nano-bio
technology development and commercialization. Previously, Dr. Iyer
worked at the UNM Medical School in Albuquerque NM and he is presently
at the Bioscience Division of the Los Alamos National Laboratory. At Los
Alamos his current focus is the blending of micro and nanotechnologies
with proteomic analysis and in the development of biologically inspired
nanoscale materials for diverse applications. He has over ten years of
research and four+ years of technical management experience and four+
years of government based commercialization experience. Through the
NSTI, he is commissioned by various US defense organizations to provide
bio-nano evaluations for funding and commercialization opportunities.
Dr. Iyer is a co-founder of the International Nanotechnology Conference
|Before May 1
||After May 1
Nanotech Impact Workshop Course Fee
Who Should Attend
These introductory - to intermediate - level courses are suitable for: Managers,
Practicing Engineers, Industrial Scientists, on a decision-making level,
Executives seeking strategic planning insight, Policy Makers with some technical
background, and Academic Researchers developing a strong nano program.
- Courses run Sunday May 7, 2006 from 8:00 am to 6:00 pm
- You may only attend a single course — please select it during registration
- Cancellations made by April 14, 2006 will be refunded less a $100.00 processing fee. Cancellations after April 14, 2006 are non-refundable.
- You may transfer your registration to another person at no charge prior to May 1, 2006. After May 1 no changes may be made.
- The running of all courses is dependent upon a minimum of 6 registrants.
- NSTI is not responsible to any instructor cancellations and subsequent changes in the program, but will make every effort to provide alternate content in the event of a cancellation.
- To register for a course, please follow the registration link.
Back to Nano Industrial Impact Workshop